KR20000069728A - 피부 패치 시트 및 그것을 위한 베이스 시트의 제조 방법 - Google Patents
피부 패치 시트 및 그것을 위한 베이스 시트의 제조 방법 Download PDFInfo
- Publication number
- KR20000069728A KR20000069728A KR1019997005815A KR19997005815A KR20000069728A KR 20000069728 A KR20000069728 A KR 20000069728A KR 1019997005815 A KR1019997005815 A KR 1019997005815A KR 19997005815 A KR19997005815 A KR 19997005815A KR 20000069728 A KR20000069728 A KR 20000069728A
- Authority
- KR
- South Korea
- Prior art keywords
- base sheet
- styrene
- film
- terephthalate film
- skin patch
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B27/08—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/30—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers
- B32B27/302—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers comprising aromatic vinyl (co)polymers, e.g. styrenic (co)polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/30—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers
- B32B27/304—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers comprising vinyl halide (co)polymers, e.g. PVC, PVDC, PVF, PVDF
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/32—Layered products comprising a layer of synthetic resin comprising polyolefins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/36—Layered products comprising a layer of synthetic resin comprising polyesters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/40—Layered products comprising a layer of synthetic resin comprising polyurethanes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B7/00—Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical properties; Layered products characterised by the interconnection of layers
- B32B7/04—Interconnection of layers
- B32B7/12—Interconnection of layers using interposed adhesives or interposed materials with bonding properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2327/00—Polyvinylhalogenides
- B32B2327/06—PVC, i.e. polyvinylchloride
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2367/00—Polyesters, e.g. PET, i.e. polyethylene terephthalate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2375/00—Polyureas; Polyurethanes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2556/00—Patches, e.g. medical patches, repair patches
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Laminated Bodies (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (15)
- 폴리염화비닐-폴리우레탄 복합체 100 중량부에 스티렌-에틸렌-부틸렌-스티렌 공중합체 2 내지 10 중량부를 배합하여 이루어지는 수지 조성물로 된 복합 필름의 한쪽 면에 접착제 층에 의하여 폴리알킬렌 테레프탈레이트 필름을 접착하여 베이스 시트로 하고, 이 베이스 시트의 폴리알킬렌 테레프탈레이트 필름의 표면에 포화 폴리에스테르 수지로 이루어지는 프라이머 층을 형성하고, 또 이 프라이머 상에 약제를 함유하는 스티렌-디엔-스티렌 블록 공중합체로 이루어지는 점착제 층을 적층하여 이루어지는 것을 특징으로 하는 피부 패치 시트.
- 제1항에 있어서, 접착제 층이 폴리우레탄 접착제로 이루어지는 두께 1.0 내지 7.0 ㎛의 층인 것을 특징으로 하는 피부 패치 시트.
- 제1항에 있어서, 폴리알킬렌 테레프탈레이트 필름이 폴리에틸렌 테레프탈레이트 필름인 것을 특징으로 하는 피부 패치 시트.
- 폴리염화비닐-폴리우레탄 복합체 100 중량부에 스티렌-에틸렌-부틸렌-스티렌 공중합체 2 내지 10 중량부를 배합하여 이루어지는 수지 조성물로 된 복합 필름의 한쪽 면에 접착제 층에 의하여 폴리알킬렌 테레프탈레이트 필름을 접착하여 이루어지는 것을 특징으로 하는 피부 패치 시트를 위한 베이스 시트.
- 제4항에 있어서, 수지 조성물이 폴리염화비닐-폴리우레탄 복합체 100 중량부에 대하여 평균 입경 3 내지 10 ㎛의 무기 미립자 5 내지 30 중량부를 포함하는 것을 특징으로 하는 피부 패치 시트를 위한 베이스 시트.
- 제5항에 있어서, 무기 미립자가 하석섬장암인 것을 특징으로 하는 피부 패치 시트를 위한 베이스 시트.
- 제4항에 있어서, 접착제 층이 폴리우레탄 접착제로 이루어지는 두께 1.0 내지 7.0 ㎛의 층인 것을 특징으로 하는 피부 패치 시트를 위한 베이스 시트.
- 제4항에 있어서, 폴리알킬렌 테레프탈레이트 필름이 폴리에틸렌 테레프탈레이트 필름인 것을 특징으로 하는 피부 패치 시트를 위한 베이스 시트.
- 제4항에 있어서, 폴리알킬렌 테레프탈레이트 필름의 표면에 포화 폴리에스테르 수지로 이루어지는 프라이머 층을 갖는 것을 특징으로 하는 피부 패치 시트를 위한 베이스 시트.
- 제4항에 있어서, 복합 필름상에 표면을 엠보스 처리한 폴리우레탄 수지 도포막으로 이루어지는 배면 처리 층을 갖는 것을 특징으로 하는 피부 패치 시트를 위한 베이스 시트.
- 폴리염화비닐-폴리우레탄 복합체 100 중량부에 스티렌-에틸렌-부틸렌-스티렌 공중합체 2 내지 10 중량부를 배합하여 이루어지는 수지 조성물을 조제하고, 이 수지 조성물을 캘린더 가공에 의해 복합 필름으로 성형하고, 이 복합 필름의 한쪽 면에 접착제 층에 의하여 폴리알킬렌 테레프탈레이트 필름을 접착하여 베이스 시트로 하고, 이 베이스 시트의 폴리알킬렌 테레프탈레이트 필름의 표면에 포화 폴리에스테르 수지로 이루어지는 프라이머 층을 형성하는 것을 특징으로 하는 피부 패치 시트를 위한 베이스 시트의 제조 방법.
- 제11항에 있어서, 수지 조성물이 폴리염화비닐-폴리우레탄 복합체 100 중량부에 대하여 평균 입경 3 내지 10 ㎛의 무기 미립자 5 내지 30 중량부를 포함하는 것을 특징으로 하는 피부 패치 시트를 위한 베이스 시트의 제조 방법.
- 제12항에 있어서, 무기 미립자가 하석섬장암인 것을 특징으로 하는 피부 패치 시트를 위한 베이스 시트의 제조 방법.
- 제11항에 있어서, 접착제 층이 폴리우레탄 접착제로 이루어지는 두께 1.0 내지 7.0 ㎛의 층인 것을 특징으로 하는 피부 패치 시트를 위한 베이스 시트의 제조 방법.
- 제11항에 있어서, 폴리알킬렌 테레프탈레이트 필름이 폴리에틸렌 테레프탈레이트 필름인 것을 특징으로 하는 피부 패치 시트를 위한 베이스 시트의 제조 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29510397 | 1997-10-28 | ||
JP97-295103 | 1997-10-28 | ||
PCT/JP1998/004850 WO1999021537A1 (fr) | 1997-10-28 | 1998-10-26 | Feuille de timbre cutane et procede de production d'une feuille de base pour timbre |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20000069728A true KR20000069728A (ko) | 2000-11-25 |
KR100719273B1 KR100719273B1 (ko) | 2007-05-18 |
Family
ID=17816342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019997005815A KR100719273B1 (ko) | 1997-10-28 | 1998-10-26 | 피부 패치 시트 및 그것을 위한 베이스 시트의 제조 방법 |
Country Status (11)
Country | Link |
---|---|
US (1) | US6267983B1 (ko) |
EP (1) | EP0968711B9 (ko) |
JP (1) | JP4395200B2 (ko) |
KR (1) | KR100719273B1 (ko) |
CN (1) | CN1152673C (ko) |
AT (1) | ATE387192T1 (ko) |
AU (1) | AU730850B2 (ko) |
CA (1) | CA2275539A1 (ko) |
DE (1) | DE69839179T2 (ko) |
TW (1) | TW518228B (ko) |
WO (1) | WO1999021537A1 (ko) |
Families Citing this family (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7897140B2 (en) | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
US7921999B1 (en) * | 2001-12-20 | 2011-04-12 | Watson Laboratories, Inc. | Peelable pouch for transdermal patch and method for packaging |
AU2003248747A1 (en) | 2002-06-27 | 2004-01-19 | Health Research, Inc. | Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy |
MY138871A (en) * | 2003-04-22 | 2009-08-28 | Sumitomo Chemical Co | Insect pest control heat vaporizing material |
US7244739B2 (en) * | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
EP1768968A1 (en) | 2004-05-20 | 2007-04-04 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
EP1765332A2 (en) * | 2004-06-17 | 2007-03-28 | Cengent Therapeutics, Inc. | Trisubstituted nitrogen modulators of tyrosine phosphatases |
EP1786421A2 (en) * | 2004-07-09 | 2007-05-23 | Cengent Therapeutics, Inc. | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases |
WO2006028970A1 (en) | 2004-09-02 | 2006-03-16 | Cengent Therapeutics, Inc. | Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
EP2433634A3 (en) | 2004-09-17 | 2012-07-18 | The Whitehead Institute for Biomedical Research | Compounds, compositions and methods of inhibiting a-synuclein toxicity |
JP4804007B2 (ja) * | 2005-01-13 | 2011-10-26 | 日東電工株式会社 | 粘着製品 |
WO2006130217A2 (en) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
ATE534652T1 (de) | 2005-04-01 | 2011-12-15 | Univ California | Phosphono-pent-2-en-1-yl-nukleoside und analoga |
US20100098640A1 (en) * | 2005-06-20 | 2010-04-22 | Cohen Seth M | Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
US8492428B2 (en) * | 2005-09-20 | 2013-07-23 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
JP5036270B2 (ja) * | 2005-12-02 | 2012-09-26 | 日東電工株式会社 | 加熱剥離型粘着シートおよびこの加熱剥離型粘着シートを用いた半導体チップの製造方法 |
BRPI0709699A2 (pt) * | 2006-03-29 | 2011-07-26 | Foldrx Pharmaceuticals Inc | inibiÇço da toxidez da alfa-sinucleina |
EA021255B1 (ru) | 2006-08-28 | 2015-05-29 | Киова Хакко Кирин Ко., Лимитед | Антагонистические моноклональные антитела человека, специфичные в отношении light человека |
US20090264421A1 (en) * | 2007-10-05 | 2009-10-22 | Bible Keith C | Methods and Compositions for Treating Cancer |
US8426587B2 (en) * | 2007-11-21 | 2013-04-23 | Pharmaxis Ltd. | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
EP2318035B1 (en) | 2008-07-01 | 2019-06-12 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
KR20170005191A (ko) | 2009-01-06 | 2017-01-11 | 큐어론 엘엘씨 | 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법 |
ES2882518T3 (es) | 2009-01-06 | 2021-12-02 | Galenagen Llc | Composición que comprende proteasa, amilasa y lipasa |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US8920392B2 (en) | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
US8404728B2 (en) | 2009-07-30 | 2013-03-26 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
US8871460B2 (en) | 2009-11-09 | 2014-10-28 | Neurogenetic Pharmaceuticals, Inc. | Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor |
US20110301235A1 (en) | 2009-12-02 | 2011-12-08 | Alquest Therapeutics, Inc. | Organoselenium compounds and uses thereof |
SG181896A1 (en) * | 2009-12-23 | 2012-07-30 | Map Pharmaceuticals Inc | Novel ergoline analogs |
EP2585455B1 (en) | 2010-06-24 | 2019-08-07 | The Regents of the University of California | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms |
ES2804223T3 (es) | 2011-04-21 | 2021-02-04 | Curemark Llc | Compuestos para el tratamiento de Trastornos Neuropsiquiátricos |
KR20140042868A (ko) | 2011-06-23 | 2014-04-07 | 맵 파마슈티컬스, 인코포레이티드 | 신규한 플루오로에르골린 유사체 |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
SG10201509139QA (en) | 2011-12-19 | 2015-12-30 | Map Pharmaceuticals Inc | Novel iso-ergoline derivatives |
SG11201403433PA (en) | 2011-12-21 | 2014-07-30 | Map Pharmaceuticals Inc | Novel neuromodulatory compounds |
ES2668300T3 (es) | 2012-05-02 | 2018-05-17 | Boehringer Ingelheim International Gmbh | Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos |
JP2015518854A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 多発性硬化症の治療のための組成物および方法 |
CN104603100A (zh) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗炎症性肠病的组合物和方法 |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
WO2013187965A1 (en) | 2012-06-14 | 2013-12-19 | Mayo Foundation For Medical Education And Research | Pyrazole derivatives as inhibitors of stat3 |
US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
US9074186B2 (en) | 2012-08-15 | 2015-07-07 | Boston Medical Center Corporation | Production of red blood cells and platelets from stem cells |
BR112015014964A2 (pt) | 2012-12-21 | 2017-07-11 | Map Pharmaceuticals Inc | novos derivados de metisergida |
US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
EP2968296B1 (en) | 2013-03-12 | 2020-09-02 | The Regents of the University of California | Gamma-secretase modulators |
AU2014274660B2 (en) | 2013-06-06 | 2019-05-16 | Pierre Fabre Médicament | Anti-C10orf54 antibodies and uses thereof |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
KR102433464B1 (ko) | 2014-05-28 | 2022-08-17 | 아게누스 인코포레이티드 | 항-gitr 항체 및 이의 사용 방법 |
EP3179857B1 (en) | 2014-08-14 | 2021-09-08 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
CA2967908C (en) | 2014-09-29 | 2020-11-17 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
WO2016067297A1 (en) | 2014-10-27 | 2016-05-06 | Cellix Bio Private Limited | Salts of valproic acid with piperazine, ethylenediamine, lysine and/or eicosapentaenoic ecid (epa) amine derivatives for the treatment of epilepsy |
EP3212626B1 (en) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US10472346B2 (en) | 2014-10-31 | 2019-11-12 | The General Hospital Corporation | Potent gamma-secretase modulators |
EP3226855A1 (en) | 2014-12-01 | 2017-10-11 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
CN114230664A (zh) | 2014-12-11 | 2022-03-25 | 皮埃尔法布雷医药公司 | 抗c10orf54抗体及其用途 |
EP3789039A1 (en) | 2014-12-22 | 2021-03-10 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
AU2016209492B2 (en) | 2015-01-20 | 2020-10-22 | Xoc Pharmaceuticals, Inc | Ergoline compounds and uses thereof |
MX2017009406A (es) | 2015-01-20 | 2018-01-18 | Xoc Pharmaceuticals Inc | Compuestos de tipo isoergolina y usos de estos. |
CN107873024A (zh) | 2015-02-09 | 2018-04-03 | 塞尔利克斯生物私人有限公司 | 用于治疗粘膜炎的组合物和方法 |
DE112016001013T5 (de) | 2015-03-03 | 2017-12-21 | Kymab Limited | Antikörper, verwendungen und verfahren |
EP3289104B1 (en) | 2015-04-29 | 2020-11-04 | New York University | Method for treating high-grade gliomas |
US10144779B2 (en) | 2015-05-29 | 2018-12-04 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
US10323091B2 (en) | 2015-09-01 | 2019-06-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
WO2017151836A1 (en) | 2016-03-04 | 2017-09-08 | East Carolina University | J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders |
EP3426301A4 (en) | 2016-03-08 | 2019-11-06 | Los Gatos Pharmaceuticals, Inc. | VERBUNDNANOPARTICLES AND USES THEREOF |
WO2017156183A1 (en) | 2016-03-08 | 2017-09-14 | Los Gatos Pharmaceuticals, Inc. | Camptothecin derivatives and uses thereof |
WO2017180794A1 (en) | 2016-04-13 | 2017-10-19 | Skyline Antiinfectives, Inc. | Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams |
DK3454904T3 (da) | 2016-05-13 | 2023-02-06 | Pasteur Institut | Inhibering af beta-2-nikotiniske acetylcholinreceptorer til at behandle patologi ved Alzheimers sygdom |
SG10201912563XA (en) | 2016-05-27 | 2020-02-27 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
JP2019525772A (ja) | 2016-07-08 | 2019-09-12 | スターテン・バイオテクノロジー・ベー・フェー | 抗apoc3抗体およびその使用方法 |
SG11201900588YA (en) | 2016-08-11 | 2019-02-27 | Cellix Bio Private Ltd | Compositions and methods for the treatment of irritable bowel syndrome |
WO2018035281A1 (en) | 2016-08-17 | 2018-02-22 | North Carolina State University | Northern-southern route to synthesis of bacteriochlorins |
CA3039125A1 (en) | 2016-10-04 | 2018-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of xerostomia |
KR20230133934A (ko) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
KR102431830B1 (ko) | 2016-11-07 | 2022-08-16 | 주식회사 뉴라클사이언스 | 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법 |
WO2018089692A1 (en) | 2016-11-09 | 2018-05-17 | Phloronol, Inc. | Eckol derivatives, methods of synthesis and uses thereof |
US10836774B2 (en) | 2016-11-30 | 2020-11-17 | North Carolina State University | Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds |
AU2017373945A1 (en) | 2016-12-07 | 2019-06-20 | Agenus Inc. | Antibodies and methods of use thereof |
MX2019006340A (es) | 2016-12-07 | 2019-11-07 | Agenus Inc | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos. |
WO2018115984A1 (en) | 2016-12-19 | 2018-06-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation |
BR112019016935A2 (pt) | 2017-02-17 | 2020-04-07 | Eidos Therapeutics Inc | processos para preparação de ag-10, seus intermediários e sais dos mesmos |
WO2018151867A1 (en) | 2017-02-17 | 2018-08-23 | CAMRIS International, Inc. | Universal antivenom |
KR102629972B1 (ko) | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
MA50957A (fr) | 2017-05-01 | 2020-10-14 | Agenus Inc | Anticorps anti-tigit et leurs méthodes d'utilisation |
AU2018275873A1 (en) | 2017-06-01 | 2019-12-19 | Xoc Pharmaceuticals, Inc. | Ergoline derivatives for use in medicine |
US10323289B2 (en) | 2017-06-26 | 2019-06-18 | Institut Pasteur | Treatments to eliminate HIV reservoirs and reduce viral load |
US11746149B2 (en) | 2017-06-27 | 2023-09-05 | Neuracle Science Co., Ltd. | Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma |
EP3645039A4 (en) | 2017-06-27 | 2021-05-05 | Neuracle Science Co., Ltd | USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS |
KR20220031738A (ko) | 2017-06-27 | 2022-03-11 | 주식회사 뉴라클사이언스 | 암 치료를 위한 항-fam19a5 항체의 용도 |
CN111315774B (zh) | 2017-06-27 | 2023-12-22 | 纽洛可科学有限公司 | 抗fam19a5抗体及其用途 |
JP2020528900A (ja) | 2017-07-27 | 2020-10-01 | アラーガン、インコーポレイテッドAllergan,Incorporated | 体脂肪低減のためのプロスタサイクリン受容体アゴニスト |
WO2019046556A1 (en) | 2017-09-01 | 2019-03-07 | East Carolina University | COMPOUNDS, COMPOSITIONS, KITS AND METHODS FOR ACTIVATING IMMUNE CELLS AND / OR AN IMMUNE SYSTEM RESPONSE |
MA50516A (fr) | 2017-10-31 | 2020-09-09 | Staten Biotechnology B V | Anticorps anti-apoc3 et leurs procédés d'utilisation |
JP7038437B2 (ja) | 2017-11-17 | 2022-03-18 | セリックス バイオ プライヴェート リミテッド | 眼障害及び皮膚疾患の処置のための化合物、組成物、及び方法 |
WO2019097318A1 (en) | 2017-11-17 | 2019-05-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of eye disorders |
AU2019239291A1 (en) | 2018-03-23 | 2020-10-08 | Eidos Therapeutics, Inc. | Methods of treating TTR amyloidosis using AG10 |
KR20240060864A (ko) | 2018-04-24 | 2024-05-08 | 주식회사 뉴라클사이언스 | 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도 |
CN112119091A (zh) | 2018-05-10 | 2020-12-22 | 纽洛可科学有限公司 | 抗序列相似家族19成员a5的抗体及其使用方法 |
BR112021000934A2 (pt) | 2018-07-20 | 2021-04-27 | Pierre Fabre Medicament | receptor para vista |
AU2019321583A1 (en) | 2018-08-17 | 2021-01-21 | Eidos Therapeutics, Inc. | Formulations of AG10 |
JP2022504287A (ja) | 2018-10-03 | 2022-01-13 | スターテン・バイオテクノロジー・ベー・フェー | ヒト及びカニクイザルapoc3に特異的な抗体、並びにその使用の方法 |
CA3119341A1 (en) | 2018-11-16 | 2020-05-22 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
US11447468B2 (en) | 2019-02-06 | 2022-09-20 | Dice Alpha, Inc. | IL-17 ligands and uses thereof |
EP4378958A2 (en) | 2019-02-26 | 2024-06-05 | Inspirna, Inc. | High-affinity anti-mertk antibodies and uses thereof |
JP2022532924A (ja) | 2019-05-20 | 2022-07-20 | ニルバナ サイエンシーズ インク. | 発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法 |
US11680098B2 (en) | 2019-08-30 | 2023-06-20 | Agenus Inc. | Antibodies that specifically bind human CD96 |
MX2022003166A (es) | 2019-09-16 | 2022-06-29 | Dice Alpha Inc | Moduladores de il-17a y usos de los mismos. |
AU2021207586A1 (en) | 2020-01-13 | 2022-07-21 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody |
JP2023512657A (ja) | 2020-02-05 | 2023-03-28 | ワシントン・ユニバーシティ | Il-7タンパク質とcar保有免疫細胞の組み合わせで固形腫瘍を治療する方法 |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
WO2022093718A1 (en) | 2020-10-26 | 2022-05-05 | Neoimmunetech, Inc. | Methods of inducing stem cell mobilization |
WO2022094475A1 (en) | 2020-11-02 | 2022-05-05 | Neoimmunetech, Inc. | Use of interleukin-7 for the treatment of coronavirus |
KR20230104175A (ko) | 2020-11-05 | 2023-07-07 | 네오이뮨텍, 인코퍼레이티드 | Il-7 단백질과 뉴클레오타이드 백신의 조합물을 사용한 종양의 치료 방법 |
US20240208968A1 (en) | 2021-03-10 | 2024-06-27 | Dice Molecules Sv, Inc. | Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof |
JP2024522213A (ja) | 2021-06-14 | 2024-06-11 | アルジェニクス ビーブイ | 抗il-9抗体及びその使用方法 |
CA3236150A1 (en) | 2021-10-22 | 2023-04-27 | Prosetta Biosciences, Inc. | Novel host-targeted pan-respiratory antiviral small molecule therapeutics |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
WO2023130081A1 (en) | 2021-12-30 | 2023-07-06 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and vegf antagonist |
US11981694B2 (en) | 2022-01-03 | 2024-05-14 | Lilac Therapeutics, Inc. | Acyclic thiol prodrugs |
US11932665B2 (en) | 2022-01-03 | 2024-03-19 | Lilac Therapeutics, Inc. | Cyclic thiol prodrugs |
GB2619907A (en) | 2022-04-01 | 2023-12-27 | Kanna Health Ltd | Novel crystalline salt forms of mesembrine |
WO2024086852A1 (en) | 2022-10-21 | 2024-04-25 | Diagonal Therapeutics Inc. | Heteromeric agonistic antibodies to il-18 receptor |
WO2024102722A1 (en) | 2022-11-07 | 2024-05-16 | Neoimmunetech, Inc. | Methods of treating a tumor with an unmethylated mgmt promoter |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3971753A (en) * | 1973-12-13 | 1976-07-27 | Union Carbide Corporation | Polymer composites and preparation thereof |
JPH02247118A (ja) * | 1989-03-17 | 1990-10-02 | Bando Chem Ind Ltd | 皮膚貼付薬シート |
JP2563846B2 (ja) * | 1990-06-28 | 1996-12-18 | バンドー化学株式会社 | 粘着シート |
JPH0725665B2 (ja) * | 1992-04-16 | 1995-03-22 | バンドー化学株式会社 | 皮膚貼付薬シートの製造方法 |
JPH0733646A (ja) * | 1993-07-23 | 1995-02-03 | Bando Chem Ind Ltd | 皮膚貼付薬シート |
JP3485701B2 (ja) * | 1995-11-06 | 2004-01-13 | 久光製薬株式会社 | 皮膚貼付用シート |
-
1998
- 1998-10-26 DE DE69839179T patent/DE69839179T2/de not_active Expired - Lifetime
- 1998-10-26 CA CA002275539A patent/CA2275539A1/en not_active Abandoned
- 1998-10-26 US US09/319,577 patent/US6267983B1/en not_active Expired - Lifetime
- 1998-10-26 WO PCT/JP1998/004850 patent/WO1999021537A1/ja active IP Right Grant
- 1998-10-26 JP JP52372899A patent/JP4395200B2/ja not_active Expired - Fee Related
- 1998-10-26 EP EP98950401A patent/EP0968711B9/en not_active Expired - Lifetime
- 1998-10-26 AU AU96484/98A patent/AU730850B2/en not_active Ceased
- 1998-10-26 KR KR1019997005815A patent/KR100719273B1/ko not_active IP Right Cessation
- 1998-10-26 AT AT98950401T patent/ATE387192T1/de not_active IP Right Cessation
- 1998-10-26 CN CNB988025140A patent/CN1152673C/zh not_active Expired - Lifetime
- 1998-10-28 TW TW087117832A patent/TW518228B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0968711A4 (en) | 2006-06-28 |
CA2275539A1 (en) | 1999-05-06 |
ATE387192T1 (de) | 2008-03-15 |
KR100719273B1 (ko) | 2007-05-18 |
CN1247468A (zh) | 2000-03-15 |
DE69839179D1 (de) | 2008-04-10 |
JP4395200B2 (ja) | 2010-01-06 |
EP0968711B1 (en) | 2008-02-27 |
US6267983B1 (en) | 2001-07-31 |
EP0968711A1 (en) | 2000-01-05 |
EP0968711B9 (en) | 2008-05-28 |
CN1152673C (zh) | 2004-06-09 |
WO1999021537A1 (fr) | 1999-05-06 |
TW518228B (en) | 2003-01-21 |
DE69839179T2 (de) | 2009-02-19 |
AU730850B2 (en) | 2001-03-15 |
AU9648498A (en) | 1999-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100719273B1 (ko) | 피부 패치 시트 및 그것을 위한 베이스 시트의 제조 방법 | |
JP2549576B2 (ja) | 粘着シート | |
JPH0725665B2 (ja) | 皮膚貼付薬シートの製造方法 | |
JP5226230B2 (ja) | 貼付剤用粘着剤組成物及びその用途 | |
JPH0635381B2 (ja) | 皮膚貼付薬シート | |
JPH0457872A (ja) | 粘着シート | |
JPH0584260A (ja) | 皮膚貼付薬シート | |
JPH064826B2 (ja) | 粘着シート | |
JPH02247118A (ja) | 皮膚貼付薬シート | |
JPH0335078A (ja) | 粘着シート | |
JP3440284B2 (ja) | 皮膚貼付薬用支持体 | |
JPH0457873A (ja) | 粘着シート | |
JPH03166280A (ja) | 粘着シート | |
JPH02166182A (ja) | 粘着シート | |
JP3345175B2 (ja) | 経皮投与薬用支持体 | |
JPH01224313A (ja) | 粘着シート | |
JPH01249719A (ja) | 皮膚貼付薬シート | |
JPH01223186A (ja) | 粘着シート | |
JPH07330589A (ja) | 経皮投与薬用支持体 | |
JPS62227983A (ja) | 粘着シ−ト | |
JPH07215845A (ja) | 経皮投与薬シート | |
JPH07215844A (ja) | 皮膚貼付薬シート | |
JPS62263275A (ja) | 粘着剤組成物 | |
JP2002166497A (ja) | 貼付材用フィルム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20060126 Effective date: 20070130 |
|
S901 | Examination by remand of revocation | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130502 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140418 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150416 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160419 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170420 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |